Recently, Inspirata, a US-based cancer diagnostics solution provider launched its India operations with their first R&D facility in Bengaluru. The company plans to help speed up cancer diagnosis, research and teaching by providing doctors and patients with predictive data that will change the way cancer is diagnosed and treated. Inspirata plans to hire 50 high-end software product development engineers, scientists and informaticists from the healthcare domain in the next two months. Satish Sanan, CEO, Inspirata tells M Neelam Kachhap more about the company and its plans for India
Tell us about Inspirata?
Inspirata is an emerging company focused on transforming cancer diagnostics by developing and delivering innovative solutions. These solutions should be affordable, scalable and create new opportunities to have a global impact on the speed and accuracy of cancer diagnoses.
What is the size of the company in terms of turnover/ revenue/ investment?
Inspirata has secured a sizeable investment and intends on growing very quickly. Just months after the launch of Inspirata’s 10,000 sq ft office in the US, a new R&D office has been opened in Bagmane Park, Bengaluru. Inspirata will start off with very modest beginnings and aspire to become a billion dollar market Cap company. Inspirata is posed to be our legacy and greatest success.
Which geographies do you operate in and what is the main focus of your growth?
Inspirata is currently operating in both the US and India, but recognises that cancer is a global epidemic. The products and solutions we offer easily cross geographic boundaries and can be distributed worldwide. Inspirata will focus its development growth in North America, Europe and India but has the long term vision of making its solutions available anywhere in the world, from the smallest villages to the most metropolitan cities. This is, in part, the power of coupling digital medicine with inexpensive tests to democratise cancer diagnostics to ensure every patient has access to a rapid and accurate diagnosis.
Tell us about data mining, data analytics and predictive software algorithms in the healthcare space?
Many governments and companies alike are interested in using Big Data for medical applications. Inspirata has identified a number of key differentiators which will add significant value to the existing databases available in the market today. These are very challenging problems with a massive upside for the consumers i.e. the patients. Learning more about how an individual’s cancer may progress or how they may respond to therapy is extremely powerful. This is the goal of precision medicine and the goal of leveraging data mining, data analytics and predictive software algorithms to transform cancer diagnostics and therapy design.
Do you think India is ready for this? What is your outlook for the Indian market?
Unfortunately, the rates of cancer findings in India are increasing rapidly. The country and its people are screaming for cheaper, more reliable cancer diagnoses. India is beginning to invest in better cancer care; however, it is also in a very unique position to take advantage of some of the newly emerging ‘leapfrog’ technologies in medicine. Inspirata believes the Indian market will be able to adopt the right solutions- which must be tailored to the Indian economy and culture.
What are your plans for Inspirata’s India operations and investment?
Currently, Inspirata’s efforts in India are focused on research and development. These are not only software development jobs but very challenging biomedical engineering and algorithm development research which are both exciting to scientists and impactful for the Indian community who would consume these products. Inspirata has adopted a philosophy of making products in India for Indians. We believe this is important and Inspirata has committed an initial investment of three million dollars towards this first initiative.
Where do you see Inspirata in the next five years?
Inspirata will never be 15-20,000 employees. Rather this company is based on a portfolio of select intellectual property which is capable of being delivered to millions of people anywhere in the world. Inspirata will be massively successful as a standard in cancer diagnostics.
- Advertisement -
Comments are closed.